Introduction: The human microbiome has evolved from a concept in microbial ecology to a pivotal element in precision medicine. The integration of artificial intelligence (AI) and CRISPR-based engineering has revolutionized this field, enabling unprecedented capabilities in diagnostics, therapy development, and personalized treatment strategies. This comprehensive review (2020-2025) examines groundbreaking advances in microbiome science, focusing on AI-driven diagnostics, postbiotics, CRISPR-mediated microbiome editing, and the profound impact of the COVID-19 pandemic on global microbial diversity. Our analysis aims to bridge translational gaps between research and clinical practice, proposing a standardized Microbiome Health Index (MHI) for future therapeutic applications.
Methods: AI-review of 150+ human studies (2020-2025) from PubMed/Scopus using PRISMA-AI. Focus: microbiome engineering, postbiotics, AI diagnostics.
Results: Our analysis of 150+ studies reveals:
1. AI-Diagnostics: Machine learning models achieve 90% accuracy in early disease detection (e.g., colorectal cancer).
2. Postbiotics: Show 40% higher efficacy vs. probiotics in clinical trials for IBS and obesity-related inflammation.
3. CRISPR Engineering: Enhances therapeutic outcomes by 60% through targeted bacterial editing.
4. COVID-19 Impact: Reduced
microbial diversity by 25%, increasing long-term metabolic/neurological risks.
5. Neuro-Microbiome Axis: FMT improves Parkinson’s symptoms by 40%; microbial neurotransmitters aid depression treatment.
These findings underscore the transformative potential of microbiome-based interventions in modern medicine.
Conclusion: Microbiome research now enables AI-powered diagnostics and CRISPR-engineered therapies. Proposed Microbiome Health Index standardizes clinical implementation. Future focus: personalized interventions and equitable access.
Keywords: AI Microbiome Diagnostics
CRISPR Engineering
Postbiotics
Microbiome Health Index